scispace - formally typeset
K

Kouji Kobiyama

Researcher at Osaka University

Publications -  68
Citations -  4144

Kouji Kobiyama is an academic researcher from Osaka University. The author has contributed to research in topics: Immune system & Innate immune system. The author has an hindex of 27, co-authored 54 publications receiving 2963 citations. Previous affiliations of Kouji Kobiyama include Daiichi Sankyo & La Jolla Institute for Allergy and Immunology.

Papers
More filters
Journal ArticleDOI

The Atg5 Atg12 conjugate associates with innate antiviral immune responses.

TL;DR: It is shown that the Atg5–Atg12 conjugate, a key regulator of the autophagic process, plays an important role in innate antiviral immune responses, thereby contributing to RNA virus replication in host cells.
Journal ArticleDOI

DNA released from dying host cells mediates aluminum adjuvant activity

TL;DR: The finding that host DNA released from dying cells acts as a damage-associated molecular pattern that mediates alum adjuvant activity may increase the understanding of the mechanisms of action of current vaccines and help in the design of new adjuvants.
Journal ArticleDOI

DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity

TL;DR: In this article, the authors show that TPT-treated cancer cells release exosomes that contain DNA that activate dendritic cells via STING signaling, and that a STING-dependent pathway drives antitumor immunity by responding to tumor cell-derived DNA.

DNA-containing exosomes derived from cancer cells treated with Topotecan activate a STING-dependent pathway and reinforce antitumor immunity

TL;DR: It is shown that treatment of breast cancer cells with the antitumor agent topotecan (TPT), an inhibitor of topoisomerase I, induces danger-associated molecular pattern secretion that triggers dendritic cell activation and cytokine production, suggesting that a STING-dependent pathway drives antitumors immunity by responding to tumor cell–derived DNA.